surmount-1 tirzepatide non-diabetic obesity weight loss For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Tirzepatide after intensive lifestyle intervention

Discuss goal weight Explain that hitting a goal weight is not a cure and that long-term treatment of some sort may be necessary

Anyone starting or continuing a compounded GLP-1 program right now should understand the FDA's April 2026 proposal, ask their telehealth platform about pharmacy structure, and have a conversation with their clinician about contingency planning for their care if compounding availability changes

Both forms deliver identical active compounds from licensed 503A compounding pharmacies, ensuring pharmaceutical quality regardless of delivery route

Insomnia is not listed among common adverse reactions in FDA prescribing information, and clinical trials did not identify it as a statistically significant side effect